What’s Going On With Sagimet Biosciences Stock On Thursday?
Sagimet Biosciences shared promising data from its FASCINATE-2 Phase 2b trial of denifanstat at the EASL Congress.
What’s Going On With Fattly Liver Disease Focused Madrigal Pharmaceuticals, Sagimet Biosciences Shares On Wednesday?
Madrigal Pharmaceuticals and Sagimet Biosciences shares fall following Eli Lilly's presentation at the EASL Liver Congress 2024. Phase 2 tirzepatide trial shows promising results for MASH treatment. Further trials needed to confirm efficacy and safety.
Alibaba To Rally Over 13%? Here Are 10 Top Analyst Forecasts For Thursday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst…
Sagimet Biosciences to Host Virtual Investor and Analyst Day on Inhibiting Fatty Acid Synthase (FASN) to Reduce Liver Fat, Inflammation and Fibrosis in MASH on May 23, 2024
Sagimet Biosciences Inc. ((Sagimet, NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today
Sagimet Announces Oral Presentation Of Data From The Phase 2b FASCINATE-2 Study Of Denifanstat In MASH At EASL International Liver Congress 2024
Sagimet Biosciences Inc. ((Sagimet, NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today
Sagimet Biosciences Announces Appointment Of Thierry Chauche As Chief Financial Officer, Effective May 6, 2024
Sagimet Biosciences Inc. ((Sagimet, NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today
Sagimet Biosciences Announces Completion Of Phase 1 Hepatic Impairment Study With FASN Inhibitor Denifanstat
Sagimet Biosciences Inc. ((Sagimet, NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today
12 Health Care Stocks Moving In Friday’s After-Market Session
Gainers Virpax Pharmaceuticals (NASDAQ:VRPX) shares increased by 13.3% to $0.37 during Friday’s after-market session. The market value of…
Why FMC Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday’s Mid-Day Session
Shares of FMC Corporation (NYSE: FMC) fell sharply during Tuesday’s session after the company reported worse-than-expected fourth-quarter results.
12 Health Care Stocks Moving In Tuesday’s Intraday Session
Gainers InVivo Therapeutics Hldg (NASDAQ:NVIV) stock rose 306.0% to $0.9 during Tuesday’s regular session. The company’s market cap…